Tambotatug pelitecan

依康坦博妥塔单抗

Report date: 2026/04/30 20:00:20

Base Information

Drug NameTambotatug pelitecan
Drug Alias NameYL-201YL201
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > Camptothecin derivative payload
Mechanisms of ActionAnti-CD276DNA topoisomerase I inhibitors
TargetsCD276 antigenDNA topoisomerase I
Therapy Area/IndicationsSolid tumoursLung DiseasesProstatic Neoplasms, Castration-Resistant +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesPoland +[12] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesMediLink Therapeutics Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesCancer Hospital Of Chinese Academy Of Medical SciencesNEXT OncologyF. Hoffmann-La Roche Ltd +[7] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursLung DiseasesProstatic Neoplasms, Castration-Resistant +[8] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A